ASH 2023 | 10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, introduces the Phase II trial (NCT04975919) assessing a 10-day treatment regimen of oral ASTX727 (decitabine/cedazuridine) with venetoclax in relapsed/refractory (R/R) acute myeloid leukemia (AML). The response duration was about 4 months, during which patients could be referred for stem cell transplantation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Current holder of stock options: Reata Pharmaceuticals
Patents & Royalties: Reata Pharmaceuticals
Consultancy: AbbVie, AstraZeneca, Genentech, Gilead, Janssen, MEI Pharma, Sanofi Aventis, Stemline-Menarini, Vincerx
Research Funding: AbbVie, Ablynx, Allogene, AstraZeneca, Cellectis, Daiichi, FortySeven, Genentech, Gilead, Immunogen, MEI Pharma, Precision Biosciences, Rafael Pharmaceutical, Sanofi Aventis, Stemline-Menarini
